

PRECEPTORSHIP PROGRAMME

METASTATIC BLADDER AND KIDNEY CANCER

Multidisciplinary management,
standards of care, therapeutic targets
and future perspectives

ZURICH
SWITZERLAND

23-24 NOVEMBER 2018

Co-Chairs Aristotelis Bamias, GR
 Camillo Porta, IT

ESMO PRECEPTORSHIP PROGRAMME METASTATIC BLADDER AND KIDNEY CANCER

Multidisciplinary management, standards of care,
therapeutic targets and future perspectives

Zurich, Switzerland
23-24 November 2018

CO-CHAIRS: Aristotelis Bamias, Greece
Camillo Porta, Italy

SPEAKERS: Maurizio Brausi, Italy
Viktor Grünwald, Germany
Dimitrios Kardamakis, Greece
Holger Moch, Switzerland
Alejo Rodriguez-Vida, Spain
Alessandro Volpe, Italy

LEARNING OBJECTIVES

To learn about fundamentals of molecular pathology and diagnosis as contributing factors to heterogeneity in bladder and kidney cancer

To understand essentials in the assessment and multidisciplinary treatment of bladder and kidney cancer

To learn about advances in treatment and novel targets in bladder and kidney cancer

ACCREDITATION

The programme of this event has been accredited with **8 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



Friday, 23 November 2018

09:00-09:15 15'	Opening and welcome	
15'	Welcome from ESMO - Objectives and scientific introduction	Aristotelis Bamias, GR Camillo Porta, IT
09:15-10:10 55'	SESSION 1 Personalized therapy in bladder cancer and Renal Cell Cancer (RCC)	Chair: Viktor Grünwald, DE
20'	The search for biomarkers in bladder cancer	Alejo Rodriguez-Vida, ES
20'	The search for biomarkers in RCC	Viktor Grünwald, DE
15'	Discussion	Faculty
10:10-10:40	Coffee break	
10:40-12:15 95'	SESSION 2 Multidisciplinary approach in metastatic urothelial cancer and RCC	Chair: Maurizio Brausi, IT
15'	The role of surgery in metastatic bladder cancer	Maurizio Brausi, IT
20'	RCC: Surgery in metastatic disease	Alessandro Volpe, IT
20'	Radiotherapy in metastatic urothelial cancer and RCC	Dimitrios Kardamakis, GR
10'	Discussion	Faculty
30'	Participants clinical case discussion (2x15')	Faculty
12:15-13:10	Lunch	
13:10-15:00 110'	SESSION 3 Metastatic disease: Systemic therapy	Chair: Camillo Porta, IT
15'	Metastatic bladder cancer: Chemotherapy	Aristotelis Bamias, GR
15'	mRCC: Anti-angiogenic therapy	Camillo Porta, IT
20'	Metastatic bladder cancer: Immunotherapy	Aristotelis Bamias, GR
20'	mRCC: Immunotherapy	Viktor Grünwald, DE
10'	Discussion	Faculty
30'	Participants clinical case discussion (2x15')	Faculty
15:00-15:30	Coffee break	

15:30-16:40 70'	SESSION 4 Debates of the day	Chair: Aristotelis Bamias, GR
20'	Systemic chemotherapy is the standard for metastatic urothelial cancer: - YES - NO	Alejo Rodriguez-Vida, ES Aristotelis Bamias, GR
15'	Discussion	Faculty
20'	Immunotherapy is the standard first-line therapy for mRCC: - YES - NO	Viktor Grünwald, DE Camillo Porta, IT
15'	Discussion	Faculty

19:00	Dinner
--------------	---------------

Saturday, 24 November 2018

09:00-10:10 70'	SESSION 5 Pathology and molecular pathology	Chair: Alejo Rodriguez-Vida, ES
20'	Bladder cancer	Holger Moch, CH
20'	Renal cancer	Holger Moch, CH
15'	Clinical application	Alejo Rodriguez-Vida, ES
15'	Discussion	Faculty

10:10-10:40	Coffee break
--------------------	---------------------

10:40-11:50 70'	SESSION 6 Side effects	Chair: Camillo Porta, IT
10'	Chemotherapy	Aristotelis Bamias, GR
15'	TKIs and mTOR Inhibitors	Camillo Porta, IT
15'	Immunotherapy	Camillo Porta, IT
30'	Participants clinical case discussion (2x15')	Faculty

11:50-12:05 15'	Conclusion and farewell	Aristotelis Bamias, GR Camillo Porta, IT
---------------------------	--------------------------------	---

12:05-13:00	Lunch
--------------------	--------------

Note: Each 15 minute slot for clinical case discussion includes 7' case presentation and 8' Q&A / panel discussion